
Re-use of subject-specific AIFs are warranted in longitudinal DCE-MRI

Christopher Larsson^{1,2}, Jayashree Kalpathy-Cramer³, Atle Bjørnerud^{1,4}, Patrick Y. Wen⁵, Tracy T. Batchelor^{6,7}, Rakesh K. Jain⁶, A. Gregory Sorensen^{3,8}, and Kyrre E. Emblem^{1,3}

TARGET AUDIENCE: Clinicians, physicists and researchers involved in imaging studies and clinical trials with longitudinal monitoring of tumor

PURPOSE: Dynamic contrast-enhanced (DCE)-MRI is widely used for assessment of tumor permeability by the capillary permeability transfer constant K^{trans} [1]. For this technique to be a valuable biomarker of response in clinical trials with repeated imaging [2], high intra-patient reproducibility is crucial to detect subtle treatment effects [3]. Because of subject-specific variations in systemic circulation, a decisive step in the estimate of K^{trans} is the selection of the arterial input function (AIF). The accuracy and reproducibility of the AIF section and subsequent K^{trans} estimation are challenged by userdependent variations, partial volume effects, image quality and choice of analysis method [1]. We hypothesize that intra-patient reproducibility of the K^{trans} estimate is maximized by re-use of a single, subject-specific AIF in comparison to traditional re-estimation at each scan or a population based AIF. **METHODS:** DCE-MRI was performed at 3T (TimTrio Siemens, Germany) with axial, fast gradient-echo images with repetition-time 5.7ms, echo-time 2.73ms, slice-thickness 2.1mm, inter-slice distance 0.4mm, in-plane resolution 2.90:2.00mm, matrix size 128:87 and 20 slices. After approximately 52s of imaging, a 0.1mmol/kg dose of gadopentetate-dimeglumine (Magnevist, Bayer Schering Pharma AG, Germany) was injected at 5cc/s. To exclude effects from T₁ variations, the T₁ values in blood and tumor were fixed at 1650ms and 1450ms, respectively. Twenty-two adult patients with recurrent glioblastoma received two baseline scans approximately four days apart with absence of intervening treatment (clinicaltrials.gov, NCT00305656) [2]. Estimates of K^{trans} were calculated in four ways: (a) with the AIF semi-automatically determined [4] at each scan (scanAIF), (b) with the AIF determined at the first scan, representing an AIF particular to the patient (patAIF), (c) with an AIF obtained as the average over all patients and scans, representing a population based AIF (popAIF) and (d) with a pre-defined and synthetic AIF (syntAIF) created in JSim (National Simulation Resource Physiome initiative) [5]. Values of K^{trans} between visits 1 and 2 were compared for all methods using Spearman correlation. Imaging analysis was performed using nordicICE (NordicNeuroLab AS, Norway).



to manually select an AIF.

RESULTS: Correlations between K^{trans}

estimated at visit 1 and visit 2 using all four arrow) from different AIFs.

methods are shown in Table 1. The patAIF method yielded the highest interscan correlations of all methods (0.94; P<0.001) followed by popAIF (0.78; P<0.001). The lowest correlation value was observed for scanAIF (0.56; P<0.01). Furthermore, the highest R^2 value was observed for patAIF (Table 1). Figure 1 illustrates examples of AIFs using scanAIF, patAIF and popAIF, respectively, as well as corresponding regional variations in K^{trans} values. **DISCUSSION:** In this study we demonstrate substantial improvements in reproducibility by revising the AIF search

strategy. A re-use of the subject-specific AIF considerably outperformed a scan-specific AIF. In addition, a population or synthetic AIFs yields higher reproducibility than a scan-specific AIF with the added value of not having

CONCLUSION: A re-use of subject-specific AIFs are warranted in longitudinal DCE-MRI.

REFERENCES: [1] Tofts PS et al, JMRI 1999;10(3):223-32, [2] Batchelor TT et al, Cancer Cell 2007;11(1):83-95, [3] Mouridsen K et al, proc ISMRM 2011 (p376), [4] Mouridsen K et al, MRM 2006;55(3):524-31, [5] Barboriak DP et al, JMRI 2008;27(6):1388-98




Figure 1. Top: Representative AIFs from a patient illustrating variations in AIF selections between visits 1 and 2. Bottom: Contrastenhanced MRI and resulting K^{trans} showing regional variations (blue

¹The Intervention Centre, Oslo University Hospital, Rikshospitalet, Oslo, Oslo, Norway, ²Faculty of Medicine, University of Oslo, Oslo, Oslo, Norway, ³Department of Radiology and Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States, ⁴Department of Physics, University of Oslo, Oslo, Norway, ⁵Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Massachusetts, United States, ⁶Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States, ⁷Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States, §Siemens Healthcare, Malvern, PA, United States